NUNZIA PHARMACEUTICAL Co (NUNZ) financial statements (2022 and earlier)
Company profile
| Business Address |
1627 WEST 14TH STREET LONG BEACH, CA 90813 |
| State of Incorp. | UT |
| Fiscal Year End | December 31 |
| SIC | 8741 - Management Services (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 9/30/2021 TTM | 12/31/2020 | 12/31/2018 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Noncurrent Assets | |||||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities, including: | 26 | 62 | |||
| Other undisclosed accounts payable and accrued liabilities | 26 | 62 | |||
| Due to related parties | 11 | 208 | |||
| Other undisclosed current liabilities | 23 | ||||
| Total current liabilities: | 36 | 294 | |||
| Noncurrent Liabilities | |||||
| Other undisclosed noncurrent liabilities | 23 | ||||
| Total noncurrent liabilities: | 23 | ||||
| Total liabilities: | 59 | 294 | |||
| Stockholders' equity | |||||
| Stockholders' equity attributable to parent, including: | (59) | (294) | |||
| Common stock | 147 | ||||
| Additional paid in capital | 92,006 | (144) | |||
| Accumulated deficit | (101,350) | (297) | |||
| Other undisclosed stockholders' equity attributable to parent | 9,285 | ||||
| Total stockholders' equity: | (59) | (294) | |||
Income statement (P&L) ($ in thousands)
| 9/30/2021 TTM | 12/31/2020 | 12/31/2018 | ||
|---|---|---|---|---|
| Operating expenses | (39) | (27) | ||
| Operating loss: | (39) | (27) | ||
| Nonoperating expense | (100,977) | |||
| Interest and debt expense | 9 | |||
| Net loss available to common stockholders, diluted: | (101,016) | (19) | ||
Comprehensive Income ($ in thousands)
| 9/30/2021 TTM | 12/31/2020 | 12/31/2018 | ||
|---|---|---|---|---|
| Net loss: | (101,016) | (19) | ||
| Comprehensive loss, net of tax, attributable to parent: | (101,016) | (19) | ||
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.